Maider Medical Industry Equipment (SH:688310) Quan Jing Wang·2025-06-05 12:22Group 1 - The core viewpoint of the news is that Maide Medical has successfully launched China's first integrated tungsten-free, glue-free, and silicone oil-free pre-filled syringe in collaboration with Nanjing Batefly, marking a significant step for domestic high-end medical consumables to enter the international market [1] - Maide Medical has developed an automated production line for Batefly, incorporating advanced technologies such as X-ray intelligent detection and micro-level collaborative control, achieving millisecond detection speed and zero glue residue risk, thus overcoming long-standing technological monopolies by foreign companies [1] - Batefly's core product, the silicone oil-free COC pre-filled syringe, has successfully passed the FDA Drug Master File (DMF) registration, indicating its readiness for international markets [1] Group 2 - Maide Medical aims to deepen strategic cooperation with industry leaders like Nanjing Batefly, leveraging its expertise in intelligent equipment to build a new ecosystem for intelligent manufacturing of medical consumables [2] - The medical device industry in China is entering a phase of high-quality development, driven by factors such as an aging population and increasing healthcare expenditures, with projections indicating that the market size may exceed 1.8 trillion yuan by 2030, with a compound annual growth rate of 7.53% from 2025 to 2030 [2] - Continuous policy support, expanding market demand, and steady improvements in production automation are creating a synergistic effect that drives the development of the intelligent medical consumables equipment industry [2] Group 3 - After over 20 years of development, Maide Medical has become a national high-tech enterprise in the medical device industry, focusing on innovation and increasing R&D investment, with R&D expenses reaching 40.41 million yuan in 2024, a year-on-year increase of 21.81% [3] - The company submitted 146 patent applications in 2024, including 21 invention patents, and received 78 new patent authorizations, with a total of 416 authorized patents by the end of 2024 [3] - In the first quarter of 2025, R&D investment was 9.156 million yuan, accounting for 22.79% of revenue, reflecting a year-on-year increase of 9.48 percentage points [3] Group 4 - Maide Medical's products have received multiple national and provincial recognitions, including being listed as key products at various levels, showcasing its commitment to quality and innovation [4] - The company is actively exploring new growth areas, including high-value medical consumables and clinical testing, while integrating advanced intelligent control systems to provide customized digital workshop solutions [4] - Maide Medical is pushing the industry towards intelligent and flexible production models, enhancing its competitive edge in the market [4]